Search | Clinical Trials Finder

Conditions: Advanced Cancer
Interventions: Relatlimab, Nivolumab, BMS-986205, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 5
States / cities: Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: Ipilimumab, Nivolumab, Radiation therapy; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions: rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Stage Non-small Cell Lung Cancer
Interventions: nivolumab, pilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Interventions: Ipilimumab, Nivolumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: AntiCD137, Ipilimumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 2 more

Conditions: Advanced Cutaneous Melanoma
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 24
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Encinitas, California + 20 more

Conditions: Brain Metastases, Renal Cell Carcinoma
Interventions: Nivolumab, Ipilimumab, Cabozantinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer Metastatic
Interventions: Nivolumab, Ipilimumab, Evolocumab; Drug
Lead sponsor: Eziafa Oduah, MD, PhD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions: Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy; Biological · Drug · Procedure + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 323
States / cities: Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 248 more

Conditions: Mesothelioma, Peritoneal Mesothelioma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Cancer
Interventions: Nivolumab, Ipilimumab, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 28
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more

Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Melanoma (Skin)
Interventions: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Cancer
Interventions: BMS-986249, Nivolumab, Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 19
States / cities: Aurora, Colorado • Denver, Colorado • Miami, Florida + 15 more

Conditions: Melanoma
Interventions: Ipilimumab, Nivolumab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Fludeoxyglucose F-18, Nab-paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab; Procedure · Drug · Other + 2 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Ipilimumab, Radiotherapy (IMRT or 3-D CRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Interventions: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Malignant Melanoma
Interventions: UV1, Sargramostim, Ipilimumab, Nivolumab; Biological
Lead sponsor: Ultimovacs ASA; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Orange, California + 16 more

Conditions: Metastatic Soft-tissue Sarcoma
Interventions: Cabozantinib, Nivolumab, Ipilimumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Stanford, California • Aurora, Colorado • St Louis, Missouri + 1 more

Conditions: Metastatic Soft-tissue Sarcoma
Interventions: Zanzalintinib, Ipilimumab, Nivolumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cancer
Interventions: Vopratelimab, Ipilimumab; Drug
Lead sponsor: Jounce Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 18
States / cities: Beverly Hills, California • Los Angeles, California • Newark, Delaware + 15 more

Conditions: Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Tampa, Florida + 5 more

Search by objective public record fields.

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations